Covenant Lite #31: KKR's Healthcare Royalty Partners Deal Signals New Front in ABF Origination Wars
Why KKR’s Healthcare Royalty Bet is the Latest Move in a Fierce Asset-Based Finance Arms Race
On July 30, KKR announced that it had acquired majority control of Healthcare Royalty Partners (“HCRx”), a prominent investor in biopharma royalties (link). By adding a specialized biopharma royalty firm to its portfolio of 18 asset-based finance platforms, KKR aims to further diversify its origination capabilities—and differentiate its credit offering from competitors like Apollo, Blue Owl and Fortress.
The deal mirrors recent high-profile moves—such as Blue Owl’s purchase of Atalaya and Brookfield’s acquisition of Castlelake—highlighting the growing urgency among institutional investors to secure proprietary deal flow for their growing asset-based finance platforms.
Origination from HCRx is likely to feed KKR’s recently closed $6.5 billion Asset-Based Finance Partners II run by Dan Pietrzak. Over time, there are likely synergies with the General Atlantic insurance platform that KKR owns, as well as with its more nascent offerings in the retail space.
Inside KKR's Healthcare Royalty Acquisition
Although specifics were not publicly disclosed in the press release, we can back into a valuation range of approximately $200–500 million using standard market comps. Here's how that works:
Assets Under Management (AUM): ~$3 billion.
Estimated Management Fee Revenues: Approximately 1%–2% of AUM, or roughly $30–$60 million annually.
EBITDA Margins: Given the lean nature of royalty investing, margins likely hover around 50%–60%, implying EBITDA in the $15–$36 million range.
Valuation Multiples: At roughly 12x–15x EBITDA (typical in asset management M&A), we arrive at a valuation range between $180 million and $540 million, aligning with industry chatter around the deal. Using the midpoint of these numbers, a valuation of $335 million seems reasonable.
KKR likely paid some amount less than this given that they purchased a majority of HCRx (rather than the platform outright). By only purchasing a majority, and having the HCRx management team roll their equity, they align their interests with the team that has built HCRx into a formidable player in healthcare royalties.
Healthcare Royalties 101: Why Investors Love Them
Healthcare royalties come in several forms, each offering unique attributes and risk-return profiles:
Traditional Royalties: Investors buy rights to a percentage of existing sales from drugs already on the market. These royalties typically provide stable, predictable cash flows with annual yields commonly ranging from 7%–12%, depending on the drug’s sales trajectory and remaining patent life.
Synthetic Royalties: Structured to replicate traditional royalties, synthetic arrangements involve financing drug development costs in exchange for a future percentage of sales. Because these deals often include clinical or regulatory milestones, they typically offer higher yields (often in the mid-teens IRR or higher) to compensate investors for increased risk.
Royalty-Backed Loans: Here, investors provide debt financing secured by royalty streams, usually with fixed interest payments plus a royalty component. These deals can yield mid-teens IRRs due to the combined elements of loan repayment certainty and royalty upside potential.
Healthcare royalties are attractive to investors (and drug companies) for a number of reasons:
Attractive Yields: With returns typically ranging from high single-digits to mid-teens IRRs, royalty streams offer compelling yields in a low-interest-rate environment.
Defensive Asset Class: Royalties are largely insulated from economic cycles, as demand for pharmaceuticals remains steady regardless of market conditions, providing investors with resilient cash flows.
Capital Efficiency for Drug Companies: Royalties offer biotechs and pharma companies a powerful non-dilutive capital alternative, allowing them to fund growth without incurring debt or equity dilution.
Collectively, these characteristics make healthcare royalties particularly appealing to institutions like pension funds, insurance companies, and private equity giants like KKR, which seek stable returns, strong downside protection, and robust growth potential.
KKR’s Grand Plan: How HCRx Fits into the Big Picture
KKR’s acquisition of HCRx strategically complements the firm's broader Asset-Based Finance strategy, significantly enhancing its origination capabilities. Following their recent $6.5 billion ABF fundraise, KKR now has substantial capital earmarked for strategic asset origination, particularly in sectors offering stable and predictable cash flows.
As discussed above, the firm already oversees 18 distinct origination platforms, each specialized in generating proprietary deal flow across asset classes. These platforms include: aviation finance (Altavair), equipment leasing (Dawsongroup), consumer loans (BMO, PayPal), music royalties (HarbourView), and real estate (SLP). KKR can now integrate biopharma royalties into its diversified asset-base. Each platform provides KKR with proprietary deal flow and unique asset sourcing capabilities, creating a robust and diversified origination ecosystem.
Integrating HCRx adds significant volume to this origination engine, allowing KKR to scale rapidly into healthcare, a sector that benefits from long-duration, predictable cash flows. They may also earmark some of the origination for KKR’s insurance arm, Global Atlantic, which manages large, yield-seeking portfolios ideally suited to stable royalty streams. By leveraging insurance capital from Global Atlantic, KKR would be able to offer more competitive pricing and larger deal sizes, positioning itself to challenge industry leaders like Royalty Pharma and Blackstone.
Moreover, the stable, cash-generative nature of healthcare royalties provides excellent raw material for KKR’s retail-oriented products, catering to high-net-worth and mass-affluent investors looking for alternative yield investments.
Competitive Landscape: How HCRx Measures Up
The healthcare royalty market is diverse, featuring a number of players with distinct investment strategies and scale:
Royalty Pharma: The industry leader, Royalty Pharma consistently originates around $2–3 billion annually. Their primary focus is on blockbuster pharmaceuticals and well-established biotech therapies, emphasizing large-scale, low-risk investments. Due to the stable, predictable nature of these assets, Royalty Pharma typically employs lower discount rates (often mid-to-high single digits), reflecting lower cash-flow uncertainty. Their significant capital resources enable them to dominate larger, high-quality transactions.
Blackstone Life Sciences: Blackstone operates across a broader spectrum, combining direct equity stakes, structured financings, and royalty streams. They typically target larger, integrated deals involving late-stage drug candidates or commercially launched products. Blackstone often leverages its extensive healthcare expertise to structure complex, hybrid financing solutions, positioning itself as a strong competitor, particularly in substantial and multi-faceted transactions.
Sagard and Other Niche Players: Firms like Sagard Healthcare Royalty Partners specialize in smaller, highly customized transactions, often focusing on niche segments or less-competitive markets. These smaller platforms prioritize flexibility and specialization, differentiating themselves by engaging in smaller deal sizes and more tailored investment approaches.
In contrast, HealthCare Royalty Partners (HCRx) strategically occupies the mid-market segment, typically originating deals in the $50–300 million range. HCRx differentiates itself through its ability to provide flexible, innovative structuring combined with rigorous scientific due diligence. Unlike Royalty Pharma’s emphasis on low-risk, blockbuster products or Blackstone’s broad and hybrid approach, HCRx targets mid-sized biopharma opportunities, often involving assets that are complex or require customized financing.
With KKR’s backing, including lower-cost capital provided by its insurance affiliate, Global Atlantic, HCRx may decide to move upstream, effectively competing for larger transactions typically dominated by players like Royalty Pharma and Blackstone.
Risks and Rewards: Navigating Complexities in Royalty Investing
While healthcare royalty investing has proven to be an attractive asset class over time, it comes with notable risks that must be carefully managed:
Patent Expiry and Revenue Declines: One of the most significant risks in royalty investing is patent expiry, often referred to as the "patent cliff." When patents expire, generic competitors quickly erode sales, drastically reducing royalty revenues. Successful royalty investors, including HCRx, proactively manage this risk by constructing diversified portfolios with staggered patent expirations.
Regulatory and Clinical Risks: Investments in earlier-stage products carry heightened regulatory and clinical risk. Failure in late-stage clinical trials or unexpected regulatory hurdles can significantly diminish projected cash flows. To mitigate these risks, sophisticated investors perform rigorous scientific and clinical diligence, carefully selecting assets with higher probabilities of regulatory approval.
Pricing Pressures and Market Dynamics: Changing reimbursement landscapes and pricing pressures can materially impact drug revenues. Investors must continually monitor evolving market conditions, regulatory changes, and payer dynamics to accurately forecast royalty streams and adapt their investment strategies accordingly.
Competition and Origination Risks: Increasing competition from well-capitalized players, including larger platforms like Royalty Pharma and Blackstone, can compress yields and make sourcing attractive transactions more challenging. KKR’s backing significantly enhances HCRx’s competitive positioning, enabling access to lower-cost capital and greater scale to effectively navigate these origination challenges.
Ultimately, navigating these complexities successfully requires thorough diligence, proactive risk management, and strategic capital deployment.
Conclusion: A New Front in the Asset-Based Finance Arms Race
KKR’s majority purchase of HealthCare Royalty Partners opens a brand‑new theatre in the battle to dominate asset‑based finance origination.
Over the past two years, rivals like Apollo, Blue Owl, Brookfield and others have scrambled to bulk up proprietary deal flow. Each acquisition is a move on the same chessboard: buy sector‑specific platforms that can manufacture high‑quality assets for captive funds and insurance balance sheets.
KKR was early to this model—its 18 existing platforms already churn out aircraft leases, equipment rentals, consumer loans, music royalties, and triple‑net real estate. By adding HCRx, KKR plants its flag in biopharma royalties—a pocket of long‑dated, IP‑backed cash flows where origination is scarce and margins are still rich. With the freshly raised ABF II fund and Global Atlantic’s low‑cost insurance capital behind it, KKR can now wield cheaper funding to win bigger royalty deals, pushing HCRx up‑market and threatening incumbents like Royalty Pharma.
The moves by the various players suggests a belief that, unlike in cashflow lending where scale dominates, ABF requires breadth of origination capabilities across collateral types. Alpha, it seems, will come from owning captive platforms that generate proprietary cashflow streams. And then fitting those cashflow streams into a diversified fund offering.
In that sense, the war for ABF supremacy just opened a powerful new front in healthcare, and KKR has fired the first volley.
Covenant Lite